Ian McGowan

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi request reprint Mucosal gene therapy using a pseudotyped lentivirus vector encoding murine interleukin-10 (mIL-10) suppresses the development and relapse of experimental murine colitis
    Hiroshi Matsumoto
    Magee Womens Research Institute, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    BMC Gastroenterol 14:68. 2014
  2. ncbi request reprint The development of rectal microbicides for HIV prevention
    Ian McGowan
    University of Pittsburgh, Department of Medicine, Pittsburgh, USA
    Expert Opin Drug Deliv 11:69-82. 2014
  3. pmc A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007)
    Ian McGowan
    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America
    PLoS ONE 8:e60147. 2013
  4. pmc Rectal microbicide development
    Ian McGowan
    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Curr Opin HIV AIDS 7:526-33. 2012
  5. doi request reprint Microbicides for HIV prevention: reality or hope?
    Ian McGowan
    Magee Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Curr Opin Infect Dis 23:26-31. 2010
  6. ncbi request reprint Heterosexual anal intercourse has the potential to cause a significant loss of power in vaginal microbicide effectiveness studies
    Ian McGowan
    University of Pittsburgh School of Medicine, Magee Womens Research Institute, 204 Craft Ave, Pittsburgh, PA 15213, USA
    Sex Transm Dis 37:361-4. 2010
  7. pmc Rectal microbicides: can we make them and will people use them?
    Ian McGowan
    Department of Medicine, Division of Gastroenterology, Haepatology, and Nutrition, University of Pittsburgh School of Medicine, 204 Craft Ave, Room B505, Pittsburgh, PA 15213, USA
    AIDS Behav 15:S66-71. 2011
  8. pmc Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004)
    Ian McGowan
    University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    AIDS 25:1057-64. 2011
  9. pmc First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy
    Peter A Anton
    Center for HIV Prevention Research, UCLA AIDS Institute, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 6:e23243. 2011
  10. pmc RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate
    Peter A Anton
    Center for HIV Prevention Research, UCLA AIDS Institute, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    AIDS Res Hum Retroviruses 28:1412-21. 2012

Detail Information

Publications14

  1. ncbi request reprint Mucosal gene therapy using a pseudotyped lentivirus vector encoding murine interleukin-10 (mIL-10) suppresses the development and relapse of experimental murine colitis
    Hiroshi Matsumoto
    Magee Womens Research Institute, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    BMC Gastroenterol 14:68. 2014
    ..This study investigates the safety and therapeutic benefit of a locally administered lentiviral vector encoding murine interleukin-10 in altering the onset and relapse of dextran sodium sulfate induced murine colitis...
  2. ncbi request reprint The development of rectal microbicides for HIV prevention
    Ian McGowan
    University of Pittsburgh, Department of Medicine, Pittsburgh, USA
    Expert Opin Drug Deliv 11:69-82. 2014
    ....
  3. pmc A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007)
    Ian McGowan
    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America
    PLoS ONE 8:e60147. 2013
    ..The MTN-007 study was designed to assess the safety (general and mucosal), adherence, and acceptability of a new reduced glycerin formulation of tenofovir 1% gel...
  4. pmc Rectal microbicide development
    Ian McGowan
    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Curr Opin HIV AIDS 7:526-33. 2012
    ..The purpose of this review is to summarize the status of rectal microbicide research and to identify opportunities, challenges, and future directions in this important field of HIV prevention...
  5. doi request reprint Microbicides for HIV prevention: reality or hope?
    Ian McGowan
    Magee Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Curr Opin Infect Dis 23:26-31. 2010
    ..This review discusses recent developments within the field of microbicide development and considers whether there are grounds to be hopeful that it will be possible to develop a microbicide for the prevention of HIV infection...
  6. ncbi request reprint Heterosexual anal intercourse has the potential to cause a significant loss of power in vaginal microbicide effectiveness studies
    Ian McGowan
    University of Pittsburgh School of Medicine, Magee Womens Research Institute, 204 Craft Ave, Pittsburgh, PA 15213, USA
    Sex Transm Dis 37:361-4. 2010
    ....
  7. pmc Rectal microbicides: can we make them and will people use them?
    Ian McGowan
    Department of Medicine, Division of Gastroenterology, Haepatology, and Nutrition, University of Pittsburgh School of Medicine, 204 Craft Ave, Room B505, Pittsburgh, PA 15213, USA
    AIDS Behav 15:S66-71. 2011
    ..The purpose of this article is to describe the challenges and progress in the development of rectal microbicides for HIV prevention...
  8. pmc Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004)
    Ian McGowan
    University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    AIDS 25:1057-64. 2011
    ....
  9. pmc First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy
    Peter A Anton
    Center for HIV Prevention Research, UCLA AIDS Institute, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 6:e23243. 2011
    ..A first-in-Phase 1 assessment of preliminary pharmacodynamics was included by measuring changes in ex vivo HIV-1 suppression in rectal biopsy tissue after exposure to product in vivo...
  10. pmc RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate
    Peter A Anton
    Center for HIV Prevention Research, UCLA AIDS Institute, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    AIDS Res Hum Retroviruses 28:1412-21. 2012
    ..On the basis of increased gastrointestinal AEs, rectally applied, vaginally formulated TFV was not entirely safe or acceptable, suggesting the need for alternative rectal-specific formulations...
  11. pmc Nonreproducibility of "snap-frozen" rectal biopsies for later use in ex vivo explant infectibility studies
    Ian McGowan
    Magee Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    AIDS Res Hum Retroviruses 28:1509-12. 2012
    ..Centralized colorectal tissue infectibility assays using biopsies from remote trial sites cannot currently be supported under these protocols...
  12. pmc Effective in vivo and ex vivo gene transfer to intestinal mucosa by VSV-G-pseudotyped lentiviral vectors
    Hiroshi Matsumoto
    Magee Womens Research Institute, Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    BMC Gastroenterol 10:44. 2010
    ....
  13. ncbi request reprint Rectal microbicides
    Ian McGowan
    aUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA bDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Curr Opin HIV AIDS 3:593-8. 2008
    ..In addition, there is increasing awareness of the need to develop rectal specific microbicide formulations...
  14. ncbi request reprint Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056)
    Ian McGowan
    Center for Prevention Research in the Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of Clifornia, Los Angeles, Los Angeles, CA, USA
    J Acquir Immune Defic Syndr 46:417-25. 2007
    ..The purpose of this study was to evaluate the biologic stability of mucosal parameters that might be used as endpoints in phase 1 rectal safety studies...